CRIS Current Research Information System

PALARETI, GUALTIERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.506
AS - Asia 4.608
EU - Europa 4.003
AF - Africa 298
SA - Sud America 267
OC - Oceania 34
Totale 15.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.443
SG - Singapore 1.660
CN - Cina 1.329
GB - Regno Unito 1.178
VN - Vietnam 677
DE - Germania 632
IT - Italia 435
SE - Svezia 380
HK - Hong Kong 330
UA - Ucraina 305
RU - Federazione Russa 264
IN - India 257
FR - Francia 203
BR - Brasile 198
IE - Irlanda 160
NL - Olanda 154
ZA - Sudafrica 101
KR - Corea 99
JP - Giappone 88
EE - Estonia 83
SC - Seychelles 67
CI - Costa d'Avorio 47
FI - Finlandia 43
ID - Indonesia 33
TG - Togo 33
AR - Argentina 32
JO - Giordania 32
CA - Canada 30
CH - Svizzera 29
MX - Messico 26
AT - Austria 25
AU - Australia 23
EG - Egitto 23
CZ - Repubblica Ceca 22
BE - Belgio 21
GR - Grecia 18
PH - Filippine 16
IQ - Iraq 14
BG - Bulgaria 12
NZ - Nuova Zelanda 11
PL - Polonia 11
BD - Bangladesh 8
CL - Cile 8
CO - Colombia 8
MA - Marocco 8
TH - Thailandia 8
MY - Malesia 7
PK - Pakistan 7
TW - Taiwan 7
ES - Italia 6
KE - Kenya 6
LB - Libano 6
PE - Perù 6
PY - Paraguay 6
RO - Romania 6
TR - Turchia 6
SA - Arabia Saudita 4
UY - Uruguay 4
UZ - Uzbekistan 4
DK - Danimarca 3
DZ - Algeria 3
EC - Ecuador 3
HR - Croazia 3
IL - Israele 3
IR - Iran 3
NG - Nigeria 3
AL - Albania 2
AZ - Azerbaigian 2
CR - Costa Rica 2
KH - Cambogia 2
LT - Lituania 2
NO - Norvegia 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BH - Bahrain 1
BW - Botswana 1
BZ - Belize 1
DO - Repubblica Dominicana 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
KZ - Kazakistan 1
LY - Libia 1
MC - Monaco 1
ML - Mali 1
MM - Myanmar 1
MU - Mauritius 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TZ - Tanzania 1
VE - Venezuela 1
Totale 15.716
Salva come PNG Salva come JPEG
Città #
Singapore 1.083
Southend 1.025
Fairfield 854
Santa Clara 526
Ashburn 524
Woodbridge 383
Chandler 376
Seattle 374
Wilmington 366
Houston 358
Hong Kong 325
Cambridge 310
Princeton 277
Hefei 259
Dong Ket 238
Ann Arbor 214
Jacksonville 201
Beijing 182
Boardman 157
Dublin 156
Nanjing 121
Westminster 111
Padova 101
Ho Chi Minh City 99
Berlin 91
Seoul 90
Tokyo 80
Hanoi 72
Los Angeles 71
Buffalo 57
Jinan 57
San Diego 54
Shenyang 53
Milan 51
Abidjan 46
Bologna 46
Dallas 45
Saint Petersburg 45
Turin 45
Hebei 41
Mülheim 39
Changsha 36
Nanchang 36
Redondo Beach 36
Dearborn 35
Munich 35
Lomé 33
Amman 32
Helsinki 32
Chicago 28
New York 27
Redmond 27
Des Moines 26
Zhengzhou 25
Bengaluru 23
Bremen 23
Frankfurt am Main 23
Mahé 23
Bern 22
Brussels 20
Tianjin 20
Al Mansurah 19
Da Nang 19
Moscow 19
São Paulo 19
Guangzhou 18
Shanghai 18
Verona 18
Hangzhou 17
Lanzhou 17
Norwalk 15
Bühl 14
Jakarta 14
Medford 14
Rome 14
Taizhou 14
Cesena 13
Falls Church 12
Jiaxing 12
Nuremberg 12
Vienna 12
Biên Hòa 11
Can Tho 11
Haikou 11
Kunming 11
Olalla 11
Phoenix 11
San Venanzo 11
Sofia 11
Taiyuan 11
Cebu City 10
London 10
Toronto 10
Yubileyny 10
Falkenstein 9
The Dalles 9
Thái Nguyên 9
Washington 9
Bangkok 8
Denver 8
Totale 10.666
Salva come PNG Salva come JPEG
Nome #
D-dimer in diagnosis and prevention of venous thrombosis: recent advances and their practical implications 390
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). 274
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. 212
Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. 191
Hereditary thrombophilia and fetal loss: a prospective follow-up study. 187
Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. 186
Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis 182
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. 177
A new rapid bedside assay for D-dimer measurement (Simplify D-dimer) in the diagnostic work-up for deep vein thrombosis. 173
Long-term efficacy of transcatheter patent foramen ovale closure on migraine headache with aura and recurrent stroke. 172
Age and gender specific cut-off values to improve the performance of D: -dimer assays to predict the risk of venous thromboembolism recurrence. 171
D-Dimer testing for predictive recurrence risk in venous thromboembolism: looking for a useful threshold: reply to a rebuttal. 164
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels. 162
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. 162
A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism. 158
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study 156
D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis 154
Familial thrombophilia and lifetime risk of venous thrombosis 153
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study 150
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study 150
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register 147
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. 146
D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 144
Bridging therapy in oral anticoagulated patients: focusing on how to do it. 144
High plasma levels of factor VIII and risk of recurrence of venous thromboembolism 144
A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage. 144
Diagnosis of deep vein thrombosis. 143
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. 143
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. 142
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 140
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 138
Analysis of agreement between duplex ultrasound scanning and arteriography in patients with lower limb artery disease 137
D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome 136
Lo studio BAFTA [The BAFTA study] 136
Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting 136
Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. 135
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. 135
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 133
External validation of the DASH prediction rule: a retrospective cohort study 133
Predictors of psychological state after genetic testing for inherited thrombophilia 132
Fibrin D-dimer testing for venous and arterial thrombotic disease 132
D-dimer testing and venous thromboembolism: four view points 131
Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. 130
Predicting the risk of recurrence of venous thromboembolism. 129
HemosIL D-dimer HS assay in the diagnosis of deep vein thrombosis and pulmonary embolism. Results of a multicenter management study. 129
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms 129
Thrombotic burden, D-dimer levels and complete compression ultrasound for diagnosis of acute symptomatic deep vein thrombosis of the lower limbs. 125
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. 125
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. 125
D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the Prolong extension study. 125
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. 124
D-dimer and reduced dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study. 123
Spontaneous large right-to-left shunt and migraine headache with aura are risk factors for recurrent stroke in patients with a patent foramen ovale. 123
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in hemodialysis patients 123
Stroke/thromboembolism and intracranial hemorrhage in a real-world atrial fibrillation population: The Complications of Atrial Fibrillation in the Bologna Area (CAFBO) study 123
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). 121
D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 120
D-dimer, oral anticoagulation, and venous thromboembolism recurrence 119
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: A prospective multicenter study 119
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. 117
VASCULAR ENDOTHELIAL DYSFUNCTION IN PRIMARY OPEN ANGLE GLAUCOMA 116
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. 115
Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). 114
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. 113
Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease? 113
Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. 112
The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study). 112
Warfarin anticoagulation in children made easier. 111
Extended treatment for venous thromboembolism: how long is long enough? 110
Risks factors for highly unstable response to oral anticoagulation: a case-control study. 109
Incidence and clinical outcomes of heparin-induced thrombocytopenia: 11 year experience in a tertiary care university hospital 108
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 108
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. 107
Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. 107
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor. 106
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 106
Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. 105
Recurrence rate after a first venous thrombosis in patients with familial thrombophilia 105
Predictors of psychological state after genetic testing for inherited trombophilia 104
The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis 104
Psychological impact of testing for thrombophilic alterations. 104
Risk factors for venous thromboembolism in the elderly: results of the master registry. 104
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants 104
The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs 103
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of a portable prothrombin time monitor (COAGUCHECK) 103
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 101
PROFILASSI DELLA MALATTIA TROBOEMBOLICA VENOSA IN CHIRURGIA BARIATRICA: STUDIO PROSPETTICO RANDOMIZZATO DI CONFRONTO TRA DUE DIFFERENTI DOSAGGI DI PARNAPARIN 100
Modulation of factor V levels in plasma by polymorphisms in the C2 domain. 100
D-dimer testing to determine the duration of anticoagulation therapy. 100
Emerging drugs for venous thromboembolism. 100
Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum) 99
Prevention of VTE in multiple myeloma patients. 98
Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, D-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis A Prospective Management Study 98
Old and new heparins. 97
Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs 97
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study: reply 96
DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register 96
The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. 94
D-dimer testing to determine the duration of anticoagulant therapy. 93
The direct oral anticoagulants may also be effective against the risk of post-thrombotic syndrome 93
Totale 13.169
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.146
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.146
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.016 0 0 0 0 0 97 48 103 163 117 84 404
2021/20221.870 199 59 169 125 224 109 49 164 70 86 273 343
2022/20231.923 244 278 112 252 119 148 53 89 285 68 175 100
2023/2024381 30 77 37 36 30 30 23 29 12 34 18 25
2024/20252.930 66 484 150 183 763 140 179 34 65 239 114 513
2025/20262.980 359 661 577 430 758 195 0 0 0 0 0 0
Totale 15.997